The Truth About Continuous Glucose Monitors: Beyond the Myths

Continuous Glucose Monitors (CGMs) have become a cornerstone of modern diabetes care, offering real-time insight into glucose dynamics that fingerstick testing simply cannot match. Yet despite their proven benefits, many people still hesitate to adopt them because of persistent myths. This article cuts through the noise, explaining what CGMs actually do, who they help, and why common fears often don't hold up under scrutiny. Whether you have diabetes, are at risk, or want to optimize your metabolic health, understanding these devices is the first step toward using them effectively.

What Exactly Is a Continuous Glucose Monitor?

A CGM is a small, wearable system that measures glucose levels in the interstitial fluid just under the skin—typically every one to five minutes. The system has three core components: a disposable sensor inserted just below the skin (usually on the abdomen or arm), a transmitter that sends data wirelessly, and a receiver such as a smartphone app, a dedicated handheld device, or a compatible insulin pump. Unlike a standard blood glucose meter that gives a single snapshot, a CGM provides a continuous stream of readings and trend arrows showing whether glucose is rising, falling, or stable.

Most modern CGMs are factory-calibrated, meaning they do not require routine fingerstick calibration. However, some older models still need occasional fingerstick checks to maintain accuracy. The sensor typically lasts 7 to 14 days, after which it must be replaced. The data is stored for retrospective analysis, allowing users and clinicians to spot patterns that would be invisible with intermittent testing.

How CGM Technology Works

The sensor uses a thin, flexible filament coated with glucose oxidase—an enzyme that reacts with glucose to produce a small electrical current. The transmitter measures this current and converts it into a glucose value using an algorithm. Because the sensor sits in interstitial fluid, there is a natural lag of about 5 to 15 minutes compared to blood glucose. This is important to remember when making rapid treatment decisions, especially during hypoglycemia. Advances in sensor design and calibration algorithms have dramatically improved accuracy in recent years, with many devices now meeting the FDA’s iCGM (integrated Continuous Glucose Monitor) standard.

Common Misconceptions About CGMs

Let’s examine the most widespread myths—and separate fact from fiction.

Myth 1: CGMs Are Only for People with Type 1 Diabetes

This is perhaps the most persistent myth. While CGMs have been a game-changer for type 1 diabetes, their utility extends far beyond that. People with type 2 diabetes—whether on insulin, oral medications, or lifestyle management—can benefit immensely. CGMs help identify post-meal spikes, dawn phenomenon, and hidden hypoglycemia from medications. Furthermore, athletes, people with prediabetes, and those following low-carb or ketogenic diets are increasingly using CGMs to fine-tune their nutrition and exercise. The FDA has approved several CGMs for non-diabetic use, and research into metabolic wellness continues to grow.

Important: If you don’t have diabetes, a CGM can still reveal how your body responds to specific foods, sleep, and stress. However, you should interpret the data with a clinician—normal glucose variability is not pathological.

Myth 2: CGMs Completely Replace Fingerstick Testing

Not entirely. Most modern CGMs (like the Dexcom G7, Abbott Freestyle Libre 3, and Medtronic Guardian 4) do not require routine calibration. However, there are scenarios where fingerstick confirmation is still recommended:

  • When symptoms of hypoglycemia do not match the CGM reading
  • During the first 24 hours of sensor warm-up
  • If the CGM reading seems inconsistent with how you feel
  • When making acute treatment decisions, such as treating low blood sugar or taking correction insulin

Some diabetes management guidelines advise that users should not rely solely on CGM data for deciding to drive or operate machinery. A fingerstick provides an immediate blood glucose snapshot, while the CGM reflects interstitial fluid with a slight delay.

Myth 3: CGM Insertion Is Painful and Uncomfortable

The insertion needle is extremely fine—many people describe it as feeling like a quick pinch. The sensor itself is soft and flexible, so once inserted, most users forget it is there. Modern applicators are designed to be one-touch and nearly painless. During the initial 24 hours, some users report mild redness or itching, but this usually resolves. The adhesive is medical-grade, and hypoallergenic options are available for sensitive skin. Over 95% of CGM users in a recent survey said the insertion discomfort was “minimal” or “nonexistent,” especially compared to the burden of multiple daily fingersticks.

Myth 4: CGMs Are Only Useful for People on Intensive Insulin Therapy

While CGMs are especially valuable for those on multiple daily injections or insulin pumps, they also help people on oral medications or no medications at all. For example, someone with type 2 diabetes on metformin may use a CGM to see how carbohydrates affect their post-meal glucose and to make informed food choices. Even if you don’t require insulin, a CGM provides real-time feedback that can motivate lifestyle changes and improve time-in-range. The American Diabetes Association now recommends CGMs for all adults with type 1 or type 2 diabetes who are on insulin, and increasingly for those on sulfonylureas or other glucose-lowering agents.

Myth 5: CGMs Are Too Expensive

The upfront cost of a CGM system—sensors, transmitter, and receiver—can indeed be high without insurance. But many factors change the picture:

  • Insurance coverage: Most commercial plans and Medicare now cover CGMs for people with diabetes who meet criteria (e.g., on insulin, history of hypoglycemia). Medicaid coverage varies by state but is expanding.
  • Long-term savings: By reducing emergency room visits, hospitalizations for DKA or severe hypoglycemia, and diabetes-related complications, CGMs often pay for themselves. A 2021 study in Diabetes Technology & Therapeutics estimated that CGM use reduced total healthcare costs by up to $2,000 per patient per year.
  • Over-the-counter options: The Abbott Freestyle Libre is available over the counter in many countries, and a prescription is not always required. Some retailers offer subscription services that lower per-sensor costs.
  • Durable equipment: The transmitter and receiver last months to years; the ongoing cost is mainly sensors and occasional transmitter replacements.

If cost is a barrier, many patients qualify for manufacturer savings programs or copay assistance cards. Discuss options with your healthcare provider and insurance company.

Myth 6: CGMs Are Inaccurate

Early CGM models had limited accuracy, but today’s sensors achieve MARD (Mean Absolute Relative Difference) values of 8–10%, which is comparable to the error range of high-quality fingerstick meters. For example, the Dexcom G7 has a MARD of 8.2% in adults; the Freestyle Libre 3 achieves around 7.9%. No glucose measurement method is perfect—both CGMs and fingersticks have inherent variability. The key is to understand that CGMs are designed for trend monitoring, not for making decisions based on a single number. Accuracy is highest in the euglycemic range and slightly lower at the extremes. Users should always double-check with a fingerstick if the CGM reading seems inconsistent with symptoms or if they plan to treat a low or high glucose level.

Myth 7: You Can’t Shower, Swim, or Exercise with a CGM

This is false. All major CGM sensors are water-resistant to at least 1 meter for 30 minutes (IPX8 rating). You can shower, swim, exercise, and even take baths while wearing the sensor. However, prolonged submersion (e.g., scuba diving) or high-pressure water (e.g., jet ski) may affect adhesion or damage the transmitter. Some manufacturers offer over-patches or adhesive wipes to improve durability during heavy sweating or water activities. The sensor is designed to stay on through normal daily wear, including during sleep.

Who Can Benefit from a CGM?

CGMs were originally developed for type 1 diabetes, but the range of beneficiaries has expanded dramatically:

  • People with type 1 diabetes – to fine-tune insulin dosing, reduce hypoglycemia, and improve A1C.
  • People with type 2 diabetes – whether on insulin, oral agents, or lifestyle management, CGMs help visualize glucose patterns and guide therapy adjustments.
  • Pregnant women with gestational diabetes – to maintain tight glucose control and reduce risks for mother and baby.
  • Endurance athletes – to manage fueling strategies and avoid hypoglycemia during long training sessions or races.
  • Individuals with prediabetes – to understand how dietary choices impact glucose and to delay or prevent progression to diabetes.
  • Health optimizers – people without diabetes who want to explore metabolic flexibility, test food responses, or improve sleep and performance.

It’s important to note that using a CGM without clinical guidance for non-diabetic purposes can lead to unnecessary worry or misinterpretation. Work with a registered dietitian or endocrinologist who understands how to use CGM data properly.

Benefits of Using a CGM

The advantages go far beyond convenience. Clinical studies consistently show improvements in glycemic outcomes and quality of life.

Real-Time Glucose Visibility

Instead of a few fingerstick numbers per day, a CGM provides hundreds of readings. This allows users to see exactly how meals, exercise, stress, and sleep affect their glucose in real time. Trend arrows indicate the direction and speed of change, enabling proactive adjustments—for example, taking a walk after a high-carb meal to blunt a spike, or having a snack before glucose drops too low.

Pattern Recognition

CGM software (e.g., LibreView, Dexcom Clarity) generates daily overlay graphs, ambulatory glucose profiles (AGP), and reports on time-in-range (TIR). TIR is now recognized as a powerful metric—studies link higher TIR (70–180 mg/dL) to lower risk of diabetes complications. Users can identify recurring issues such as nighttime hyperglycemia, post-breakfast spikes, or exercise-induced hypoglycemia and work with their care team to adjust medication or lifestyle.

Alerts and Alarms

Customizable alarms for high and low thresholds, as well as rate-of-change alerts, prevent dangerous episodes. For example, an urgent low alarm (e.g., below 55 mg/dL) can wake a user from sleep, while a predictive low alarm gives a 20-minute warning before hypoglycemia occurs. These alerts reduce the strain of constant vigilance and can be life-saving for people with hypoglycemia unawareness.

Improved Glycemic Control

Multiple large randomized controlled trials—including the DIAMOND study (2017) and the REPLACE-BG trial—have demonstrated that CGM use leads to clinically significant reductions in A1C (0.3–0.6%) and reductions in time spent in hypoglycemia, regardless of insulin delivery method. A meta-analysis published in Diabetes Care (2020) concluded that CGM improves glycemic control across all age groups and diabetes types.

Convenience and Reduced Fingerstick Burden

For many, the psychological relief of not having to prick fingers multiple times a day is enormous. With each sensor lasting 7–14 days, the day-to-day burden of diabetes management drops significantly. Users report less anxiety about unknowns and greater confidence in making decisions.

Limitations to Consider

No technology is perfect, and honesty about limitations helps set realistic expectations.

  • Lag time: Interstitial fluid glucose lags behind blood glucose by 5–15 minutes. This means a CGM may underestimate a rapidly dropping glucose level, especially during intense exercise or early hypoglycemia.
  • Accuracy at extremes: Some CGMs are less accurate in the hypoglycemic range (< 70 mg/dL) and may read lower or higher than actual blood glucose. Always confirm with a fingerstick if the number is critical.
  • Sensor insertion errors: Occasionally a sensor fails (connects incorrectly, loses signal, or dislodges). Users should always have a backup plan—carrying a blood glucose meter and strips is still recommended.
  • Skin reactions: Some users develop irritation from the adhesive. Rotating insertion sites, using barrier wipes, or switching to hypoallergenic patches can help.
  • Data overload: The sheer volume of data can be overwhelming. It takes education to interpret patterns without chasing every blip. Over-interpreting minor fluctuations can lead to unnecessary treatment changes.
  • Cost and access: Despite improvements, cost remains a barrier for many, especially those without insurance or in lower-income settings. Advocacy for wider coverage continues.

How to Choose the Right CGM

Selecting a CGM involves several factors. Here’s a breakdown:

Sensor Duration and Replacement Frequency

Most sensors last 7 days (Dexcom G6/G7) or 14 days (Freestyle Libre 2/3, Dexcom G7). Medtronic’s Guardian 4 lasts 7 days. Longer-lasting sensors mean fewer insertions and lower inconvenience. Some users prefer the 14-day option for lower hassle; others find the 7-day sensor more accurate in the second week.

Accuracy and MARD

While all modern CGMs are highly accurate, the Freestyle Libre 3 and Dexcom G7 are among the best with MARD around 8%. Medtronic Guardian 4 is slightly higher (9–10%). Accuracy matters more if you have hypoglycemia unawareness or need to make precise insulin adjustments.

Integration with Insulin Pumps and Smart Devices

If you use an insulin pump, check compatibility. Dexcom works with Tandem t:slim X2 (control-IQ) and Omnipod 5. Medtronic CGM integrates with their own pumps. Freestyle Libre 2/3 communicates with compatible insulin pens and third-party apps. For smartphone use, all major CGMs have iOS/Android apps with real-time displays, but some require a dedicated receiver (e.g., Libre 2 receiver is optional).

Cost and Insurance Coverage

Contact your insurance provider to see which CGMs are covered under your plan. Check the manufacturer’s patient assistance or savings programs. For example, Abbott offers a Libre savings card; Dexcom has a copay assistance program. Out-of-pocket costs vary widely—from $35/month with insurance to over $200/month without.

Data Sharing and Remote Monitoring

Parents of children with diabetes often prioritize remote monitoring features. Dexcom Share allows real-time sharing with up to 10 followers; LibreLinkUp does the same. Medtronic’s CareLink enables data review by clinicians. Consider whether you need this feature.

User Reviews and Real-World Experience

Check forums, diabetes communities, and peer-reviewed studies. Online sources like the American Diabetes Association and diabetes.org provide unbiased comparisons. Also, ask your endocrinologist or diabetes educator for recommendations based on your lifestyle.

The Future of Continuous Glucose Monitoring

The field is evolving rapidly. Emerging trends include:

  • Fully factory-calibrated sensors with no user calibration needed—already here with Libre 3 and Dexcom G7.
  • Implantable CGMs (e.g., Eversense) that last up to 180 days and are inserted in-clinic.
  • Non-invasive optical sensors that measure glucose through the skin without a filament—still in development but promising.
  • Integration with smartwatches that display real-time glucose and trend arrows directly on the wrist.
  • Artificial pancreas systems that combine CGM with automated insulin delivery, mimicking the function of a healthy pancreas.
  • Multi-analyte sensors that measure ketones, lactate, or other biomarkers alongside glucose.

Research is also expanding into using CGM data for early detection of prediabetes, assessing the impact of dietary patterns on metabolic health in the general population, and even managing other conditions like non-alcoholic fatty liver disease.

Conclusion

Continuous Glucose Monitors are far more than a niche device for type 1 diabetes. They provide actionable, data-driven insights that can transform diabetes management, prevent dangerous complications, and improve quality of life for a broad spectrum of users. The myths that persist—about cost, pain, accuracy, and scope—are largely outdated or exaggerated. With improved sensor technology, wider insurance coverage, and a growing body of clinical evidence, a CGM is now a standard-of-care tool. If you are living with diabetes or want to optimize your metabolic health, talk to your healthcare provider about whether a CGM is right for you. Understanding the facts is the first step toward harnessing the power of continuous glucose data.